<DOC>
	<DOCNO>NCT01238939</DOCNO>
	<brief_summary>The primary objective determine maximum tolerate dose/recommended phase II dose combination regimen NK012 5-fluorouracil patient advance solid tumor .</brief_summary>
	<brief_title>Study NK012 5-FU/LV Solid Tumors Followed Dose Expansion Colorectal Cancer</brief_title>
	<detailed_description>On Day 1 28 day cycle , NK012 administer 30 minute IV infusion , follow continuous infusion 5-FU 46 hour . On Day 15 cycle , patient receive 5-FU continuous infusion . Treatment expect continue 6 cycle , unless disease progression development unacceptable toxicity require discontinuation drug . At discretion investigator , patient show sign benefit may continue beyond 6 cycle . Once MTD/RD determine combination regimen , dose expansion cohort patient metastatic colorectal cancer treat determined MTD . ( Prior Amendment 2 , patient receive NK012 5-FU leucovorin ( LV ) . The dose regimen change Amendment 2 NK012 5-FU . )</detailed_description>
	<mesh_term>Colorectal Neoplasms</mesh_term>
	<criteria>1 . Histologically cytologically confirm diagnosis advance solid tumor efficacious therapy exists , camptothecinbased regimen would appropriate . 2 . For dose expansion MTD/RD : 1 . The patient must fail oxaliplatinbased first line therapy metastatic colorectal cancer . This include patient fail oxaliplatinbased therapy progressive disease , well patient , base toxicity MD/patient discretion , long candidate oxaliplatin . Patients fail adjuvant therapy oxaliplatinbased chemotherapy regimen within one year last dose oxaliplatinbased chemotherapy also consider eligible study . 2 . Patients must one prior chemotherapy regimen metastatic setting . Patients radiosensitizing chemotherapy radiation treatment treatment count prior chemotherapy regimen . 3 . Patients must measurable disease RECIST ( version 1.1 ) . 3 . Patient must recover acute adverse effect prior therapy , exclude alopecia . 4 . For patient enrol dose escalation phase , 4 prior cytotoxic regimen metastatic setting . 5 . Prior irradiation 25 % bone marrow . 6 . ECOG performance status 01 . 7 . Life expectancy least 12 week . 8 . Patients least 18 year age . 9 . Adequate bone marrow function define ANC ≥ 1500/mm^3 platelet count ≥ 100,000/mm^3 . 10 . AST ALT ≤ 3.0 x ULN ( 5 x ULN document liver metastasis ) total bilirubin ≤ 1.5 x ULN . 11 . Serum creatinine ≤ 1.5 x ULN , creatinine clearance ≥ 60 mL/min CockcroftGault formula* patient serum creatinine &gt; 1.5 x ULN . *CockcroftGault formula creatinine clearance ( CrCl ) : Males : CrCl ( ml/min ) = ( 140 age ) x wt ( kg ) / ( serum creatinine x 72 ) Females : Multiply result 0.85 12 . Able understand show willingness sign write informed consent document . 1 . Prior chemotherapy , radiation therapy , investigational therapy within 4 week ( exception : 6 week nitrosoureas mitomycin C ) ; prior noncytotoxic therapy within 5 drug halflives ( 4 week , ever short ) ; monoclonal antibody within 4 week prior first dose study treatment . 2 . Concurrent use investigational agent . 3 . History brain metastasis spinal cord compression , unless irradiate treat minimum 4 week prior first study treatment stable without requirement corticosteroid &gt; 1 week . 4 . Concurrent serious infection require parenteral antibiotic therapy . 5 . Pregnant childbearing potential use method avoid pregnancy . A negative pregnancy test must document baseline woman childbearing potential . Patients may breastfeed infant study . 6 . Significant cardiac disease include heart failure meet NYHA class III IV definition , history myocardial infarction within 6 month study entry , uncontrolled dysrhythmias poorly control angina . 7 . History serious ventricular arrhythmia ( VT VF , ≥ 3 beat row ) , QTc ≥ 450 msec men 470 msec woman , LVEF ≤ 40 % MUGA ECHO . 8 . History allergic reaction attribute compound topoisomerase I inhibitors . 9 . Prior treatment irinotecan .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>November 2014</verification_date>
	<keyword>solid tumor</keyword>
	<keyword>colorectal cancer</keyword>
</DOC>